Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2000-07-26
2003-02-04
Wilson, James O. (Department: 1623)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C514S171000, C514S177000, C514S178000, C514S179000, C514S262100, C514S263300, C514S264100, C514S105000, C514S931000, C514S934000
Reexamination Certificate
active
06514980
ABSTRACT:
This invention relates to the use of a nucleoside analogue active against herpes simplex virus (HSV), in the treatment of herpes simplex virus infections, and to pharmaceutical compositions containing the two components.
The disease indication for herpes simplex subtype 1 (HSV-1) is herpes labialis (cold sores), and the disease indication for herpes simplex subtype 2 (HSV-2) is genital herpes.
Herpes Labialis is a common world-wide disease characterized by repeated attacks of versicular eruptions most commonly recognised on the lips and perioral skin. Many patients report pain, swelling and significant cosmetic concerns associated with subsequent ulceration of lesions. Although generally a minor disease, in some patients the consequences of frequent severe attacks can be debilitating. The disease is naturally self-limiting in immunecompetent individuals and recurrent episodes last 7-10 days.
First infection with genital herpes may be severe (primary first episode) if the patient has no previous history of labial or genital herpes infection, while a less severe disease occurs if any antibody response is developed through previous exposure to HSV—non-primary first episode. The most common sequel to primary genital herpes infection is recurrent disease. The attack rate varies greatly but is likely that patients will experience on average 4-5 episodes per year. Symptomatology in these episodes are characterised by painful lesions which progress from papules and vesicles through to ulcers and finally crusts. Lesions may be accompanied by a range of symptoms including pain, tenderness, itching and swelling of the affected area.
EP-A-141927 (Beecham Group p.l.c.) discloses penciclovir, the compound of formula (A):
and salts, phosphate esters and acyl derivatives thereof, as antiviral agents. The sodium salt hydrate of penciclovir is disclosed in EP-A-216459 (Beecham Group p.l.c.). Penciclovir and its antiviral activity is also disclosed in Abstract P.V11-5 p.193 of ‘Abstracts of 14th Int. Congress of Microbiology’, Manchester, England Sep. 7-13, 1986 (Boyd et. al.).
Orally active bioprecursors of the compound of formula (A) are of formula (B):
and salts and derivatives thereof as defined under formula (A); wherein X is C
1-6
alkoxy, NH
2
or hydrogen. The compounds of formula (B) wherein X is C
1-6
alkoxy or NH
2
are disclosed in EP-A-141927 and the compounds of formula (B) wherein X is hydrogen, disclosed in EP-A-182024 (Beecham Group p.l.c.) are preferred prodrugs. A particularly preferred example of a compound of formula (B) is that wherein X is hydrogen and wherein the two OH groups are in the form of the acetyl derivative, described in Example 2 of EP-A-182024, hereinafter referred to as famciclovir.
The compounds of formulae (A) and (B) and salts and derivatives thereof have been described as useful in the treatment of infections caused by herpesviruses, such as herpes simplex type 1 and herpes simplex type 2. All references herein to penciclovir/famciclovir include pharmaceutically acceptable salts, such as the hydrochloride, and solvates, such as hydrates.
When used herein the term ‘immunosuppressant’ includes pharmaceutical agents such as cytotoxic agents such cyclophosphamide and cyclosporin A and corticosteroids such as hydrocortisone and dexamethasone and non steroidal anti-inflammatory agents.
In one preferred aspect, the immunosuppressant is cyclosporin A.
The anti-herpes simplex virus properties of nucleoside analogues such as penciclovir/famciclovir or ayclovir/valaciclovir are potentially enhanced by administering the compound in conjunction with an immunosuppressant. The rationale is that in mice infected with herpes simplex virus, treatment with an antiviral agent to achieve clearance of the virus is particularly effective when the mice are immunosuppressed with cyclosporin A.
REFERENCES:
patent: 3317384 (1967-05-01), Underwood et al.
patent: 5508310 (1996-04-01), Rhodes
patent: 6136835 (2000-10-01), Camden
patent: 1 099 385 (1968-01-01), None
patent: WO 91/11187 (1991-08-01), None
patent: WO 92/00742 (1992-01-01), None
patent: WO 96/19482 (1996-06-01), None
patent: WO 96/24355 (1996-08-01), None
McKeough et al., “Combination of Peroral Famciclovir and a Topical Cortocosteroid for the Treatment of Experimental Ultraviolet Radiation (UVR)-Indiced Herpes Labialis: A Double-Blind, Placebo-Controlled Trial.”, 39th Annual ICAAC, San Francisco, CA, Abstracts 1408 (1999).
Awan et al., “Combinations of Antiviral and Anti-Inflammatory Preparations for the Topical Treatment of Herpes Simplex Virus Assessed Using a Murine Zosteriform Infection Model”, Antiviral Chemistry & Chemotherapy, vol. 9, pp. 19-24 (1998).
Thackray et al., “The Influence of Cyclosporin Immunosuppression on the Efficacy of Famciclovir or Valaciclovir Chemotherapy studied in a Murine Herpes Simplex Virus Type 1 Infection Model”, vol. 8, No. 4, pp. 317-326 (1997).
Field et al., “Can Herpes Simplex Virus Latency be Prevented Using Conventional Nucleoside Analogue Chemotherapy?”, Antiviral Chemistry & Chemotherapy, vol. 8, Suppl. 1, pp. 59-66 (1997).
Murakami et al., “Bell Palsy and Herpes Simplex Virus: Identification of Viral DNA in Endoneurial Fluid and Muscle”, Ann. Intern. Med., vol. 124, No. 1, Pt. 1, pp 27-30 (1996).
Baringer, “Herpes Simplex Virus and Bell Palsey”, Ann. Intern. Med., vol. 124, No. 1, Pt. 1, pp 63-65 (1996).
Field et al., “Effects of Cyclosporin Immunosuppression on the Efficacy of Antiviral Chemotherapy Studied in a Murine Infection Model for HSV-1.”, Clin Vet. Med., pp. 1-11 (1996).
Field et al., ECC GlasGow Presentation, Abstract, May 1996.
,,, pp. 192-193, 206-207 (1993).
Choi et al., “Enhanced Transdermal Delivery of Propranolol, Hydro-Cortisone, Acyclovir and Peptide-Type Drugs.”, Dissertation Abstracts International, vol. 50, No. 8, pp 3422-B (1990).
Peters, “Immunological Aspects of Antiviral Therapy”, Sprinter Semin. Immunopathol., vol. 12, pp. 47-56 (1990).
Hilfenhaus et al., “Combined Antiviral Effects of Acyclovir or Bromovinyldeoxyuridine and Human Immunoglobulin in Herpes Simplex Virus-Infected Mice”, Antiviral Research, vol. 7, pp. 227-235 (1987).
Schinazi et al., “Studies in vitro and in vivo of Combinations of Antivirals and Anti-inflammatory Agents in Relation to the Treatment of Herpes Simplex Viruses,” Chemical Abstract, 97:156002r, Curr. Chemother. Immunother., Proc. Int. Congr. Chemother., 12th, 1981 (Publ. 1982). 2, pp. 1085-1087.
Ikeda et al., “Antiherpes Activity of Chemically Synthesized Lipid A-subunit Analogue GLA-60 in Immunosuppressed Mice, ”Antiviral Research, vol. 11, pp. 173-180 (1989).
Nomura et al., “Two Cases of Encephalo-Myelo-Radiculoneuropathy, Triggered by Herpes Simplex Virus Type-1 Infection,” Abstract (Medline), Clinical Neurology, vol. 37(7) pp. 621-625 (1997).
Field et al., “Comparison of Efficacies of Famciclovir and Valaciclovir against Herpes Simplex etc.,” Antimicrobial Agents and Chemotherapy, vol. 39(5), pp. 1114-1119 (1995).
Field et al., “The Effects of Delayed-Onset Chemotherapy Using Famciclovir or Valaciclovir etc.,” Antiviral Chemistry & Chemotherapy, vol. 6(4) pp. 210-216 (1995).
Novartis International Pharmaceutical Ltd.
Savitsky Thomas R.
Wilson James O.
LandOfFree
Nucleoside analogs in combination therapy of herpes simplex... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Nucleoside analogs in combination therapy of herpes simplex..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Nucleoside analogs in combination therapy of herpes simplex... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3169106